Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Acute and subchronic testing in mice indicates limited systemic toxicity for GLG-V-13

Feb. 17, 2000

Pharmacyclics' texaphyrins now claimed for use in macrophage-mediated conditions

Feb. 17, 2000

Guanylate cyclase-activating agents in early development at Aventis

Feb. 17, 2000

Alexion and Brigham & Women's Hospital to develop novel antiinflammatory antibody

Feb. 17, 2000

Novel gene therapy reverses atherosclerotic process in mice

Feb. 17, 2000

German researchers disclose new agents for hypertension

Feb. 16, 2000

FDA grants Merck & Co. marketing exclusivity extension for Vasotec

Feb. 16, 2000

Potent and selective ETA antagonist selected as development candidate

Feb. 15, 2000

Millennium uncovers role of Madh6 gene in cardiovascular defects

Feb. 15, 2000

Novel Warner-Lambert compounds act as inhibitors of Lp(a) production

Feb. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...